Description
E.P.T.Q S500 with Lidocaine is a high-density, fully cross-linked hyaluronic acid (HA) dermal filler designed for deep volume restoration, facial contouring and structural augmentation. With a concentration of 24 mg/ml HA and 0.3% lidocaine, the filler offers high viscoelasticity and lift capacity, making it suitable for augmenting cheeks, chin, jawline and correcting severe volume loss. Its highly purified HA formulation is manufactured under the e.p.t.q. “9 Essentials” process to ensure low endotoxin (<0.1 EU/ml) and minimal residual cross-linking agents (BDDE), aiming for safety and durability of results. The product is supplied as a 1.1 ml pre-filled syringe with 27G (or 25G) needle, and must be administered by a licensed practitioner under aseptic conditions.
Bnefits
- High-density HA filler provides strong lifting and volume restoration for areas with deep volume loss (cheeks, chin, jawline, mid-face).
- Contains 0.3% lidocaine to reduce injection discomfort and increase patient comfort during treatment.
- High viscoelasticity and cross-linked, cohesive gel structure allow precise sculpting and stable contouring.
- Manufactured under strict purification process (“9 Essentials”) with endotoxin < 0.1 EU/ml and low residual BDDE, reducing risk of inflammation or adverse reactions.
- Long-lasting results—effect duration reportedly up to 12–18 months depending on treatment area and patient factors.
- CE-marked for safety and compliance with European medical device regulations (where applicable).
Indications
- Facial augmentation in areas with volume deficiency (cheeks, mid-face, temples, chin, jawline).
- Correction of age-related volume loss and skin sagging / hollowing.
- Deep wrinkle and fold correction (e.g. nasolabial folds, marionette lines) when greater lift and volume needed.
- Non-surgical contouring procedures such as cheekbone enhancement, chin and jawline definition.
- Structural support beneath the skin (supraperiosteal or deep dermal/subcutaneous planes) for significant reshaping or augmentation.
Composition
- Cross-linked hyaluronic acid, 24 mg/ml (non–animal origin)
- Lidocaine hydrochloride 0.3% for local anaesthesia / comfort
- Buffered physiological solution (sterile saline-based carrier; exact buffer components proprietary)
Packaging
- 1 x 1.1 ml pre-filled sterile syringe containing E.P.T.Q S500 filler
- Includes 1 x 27G (or 25G) sterile needle (or as specified by supplier)
- Packaged in a sealed sterile blister/carton with batch number, expiry date and instructions for use
Usage
- Should be used only by trained and qualified healthcare professionals under aseptic conditions.
- Perform a full assessment including patient history, allergies, previous filler treatments, and anatomical considerations before injection.
- Cleanse and disinfect the area thoroughly; maintain aseptic technique throughout procedure.
- Inject at deep dermal / subcutaneous or supraperiosteal plane depending on indication, using recommended needle size (25G or 27G) or cannula if appropriate.
- Use small aliquots, minimal pressure, and aspirate before injection to avoid intravascular placement.
- Massage gently if required to shape and contour the treated area, following clinic protocol.
- Advise patient to avoid strenuous exercise, excessive heat or alcohol, and to follow aftercare guidelines for 24-48 hours or as per protocol.
- Ensure readiness for potential complications, including vascular occlusion, and have appropriate reversal/management protocols available.
Contraindications
- Hypersensitivity to hyaluronic acid, lidocaine, or any other components of the product.
- Active skin infection, inflammation or lesions at the intended injection site.
- History of severe allergic reactions or anaphylaxis, unless risk assessment and emergency measures in place.
- Bleeding disorders or concurrent anticoagulant/antiplatelet therapy that increases risk of bleeding or bruising (relative contraindication).
- Pregnancy or breastfeeding (lack of safety data).
- Previous permanent or non-resorbable fillers in the same area without adequate evaluation — risk of interaction/complication.
Adverse Effects
- Common injection site reactions: swelling, redness, bruising, tenderness, pain, itching, mild induration or asymmetry.
- Temporary lumps or nodules under the skin; may require massage or further management.
- Local haematoma or ecchymosis due to needle/cannula trauma or vascular injury.
- Rare but serious risks: vascular occlusion, tissue ischaemia or necrosis if inadvertently injected into or compressing a vessel, possible vision impairment if filler enters arterial circulation.
- Delayed hypersensitivity or inflammatory reactions possibly triggered by residual cross-linker or external factors.
- Risk of infection or biofilm formation if aseptic technique is not strictly followed.
Storage Conditions
- Store between 2 °C and 25 °C in a dry place, protected from direct sunlight.
- Do not freeze.
- Keep the syringe sealed in its original packaging until use to maintain sterility.
- Use before the expiry date printed on the carton.
Duration
Effects typically last between 12\u201318 months, depending on treatment area, injection volume, patient metabolism and lifestyle.
Onset
Visible volume restoration and contouring are immediate after injection; final aesthetic result emerges over 1\u20132 weeks as swelling subsides. (Common to cross-linked HA fillers)
